文献速递精神分裂症与精神病性障碍

抗精神病药减少精神分裂症攻击行为的比较疗效:系统综述与网络荟萃分析

Comparative efficacy of antipsychotics for reducing aggression in schizophrenia: systematic review and network meta-analysis.
PubMed 文献 · Br J Psychiatry · 2026-09-24

与安慰剂相比,氯氮平、帕利哌酮和奥氮平效应量最大,但证据确信度低或极低。

要点

  • 与安慰剂相比,氯氮平、帕利哌酮和奥氮平减少敌意与攻击行为的效应量最大。
  • 阿塞那平、利培酮、阿立哌唑和氟哌啶醇也有较小但显著的效应。
  • 证据确信度低或极低,主要源于研究内偏倚和不一致性。

核心结论

  • 抗精神病药可减少精神分裂症患者的敌意与攻击行为,研究以中短期为主。
  • 氯氮平、帕利哌酮和奥氮平似乎最有效,但低确信度证据限制了对药物间差异的结论。

研究设计与样本

  • 系统综述与频率学随机效应网络荟萃分析,方案在PROSPERO注册(CRD42024572272)。
  • 检索PubMed、PsycINFO、ClinicalTrials.gov和Cochrane精神分裂症组注册库至2025年4月25日。
  • 纳入成人精神分裂症或相关精神病性障碍的随机对照试验,评估敌意或攻击行为且随访≥48小时。

主要发现

  • 与安慰剂相比,氯氮平(SMD -0.75,95% CI -1.13至-0.38)、帕利哌酮(-0.62,-0.88至-0.36)和奥氮平(-0.60,-0.86至-0.35)效应量最大。
  • 阿塞那平、利培酮、阿立哌唑和氟哌啶醇也有较小但显著的效应(SMD范围-0.52至-0.30)。
  • 最常用结局指标为症状评定量表中的敌意条目或相关子量表(36/41,88%)。

关键数值与推荐

  • 采用标准化均数差(SMD)合并效应量,使用CINeMA评估证据确信度。
  • 证据确信度低或极低,主要由于研究内偏倚和不一致性。

临床怎么用

  • 针对精神分裂症患者的敌意与攻击行为,可优先考虑氯氮平、帕利哌酮或奥氮平。
  • 临床决策需结合低确信度证据,个体化权衡疗效与安全性。

局限性

  • 证据确信度低或极低,限制了对不同抗精神病药之间差异的结论。
  • 多数研究随访为短期至中期,且以敌意条目或子量表而非攻击行为为主要结局。
  • 需要以攻击行为为主要结局、随访更长的进一步试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antipsychotics are used to manage hostility and aggressive behaviour in schizophrenia, but their comparative efficacy remains unclear. AIMS: To compare the efficacy of antipsychotics for reducing hostility and aggressive behaviour in schizophrenia. METHOD: We searched PubMed, PsycINFO, ClinicalTrials.gov, and the Cochrane Schizophrenia Group's register to 25 April 2025. Two reviewers screened studies and extracted data. We included randomised controlled trials in adults with schizophrenia or related psychotic disorders assessing hostility or aggressive behaviour with ≥48 h follow-up. Standardised mean differences (SMDs) were synthesised in a frequentist random-effects network meta-analysis. Confidence was assessed using Confidence In Network Meta-Analysis. The protocol was registered in PROSPERO (CRD42024572272). RESULTS: Forty-one studies involving 21 025 participants and 18 antipsychotics were included. Most studies were based on double-blind, parallel-group trials (37/41, 90%), with a median follow-up of 8 weeks (interquartile range = 6). The most common outcome measures were hostility items or related subscales from symptom rating scales (36/41, 88%). Compared with placebo, several antipsychotics reduced hostility and aggressive behaviour. Clozapine (SMD -0.75, 95% CI -1.13 to -0.38), paliperidone (-0.62, -0.88 to -0.36), and olanzapine (-0.60, -0.86 to -0.35) showed the largest effects. Smaller but significant effects were observed for asenapine, risperidone, aripiprazole and haloperidol (SMD range -0.52 to -0.30). Confidence in the evidence was low or very low, mainly due to within-study bias and incoherence. CONCLUSIONS: Antipsychotics reduced hostility and aggressive behaviour in predominantly short- to medium-term studies. Clozapine, paliperidone and olanzapine appeared most effective, although low-certainty evidence limits conclusions about differences between antipsychotics. Further trials with aggressive behaviour as the primary outcome and longer follow-up are needed.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Lamsma J, Ostinelli EG, Cipriani A, et al. Comparative efficacy of antipsychotics for reducing aggression in schizophrenia: systematic review and network meta-analysis. Br J Psychiatry. 2026. PMID: 42781780. doi:10.1192/bjp.2026.10800

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。